Biomarkers, Esophageal Squamous Cell Carcinoma, Immunotherapy
Conditions
Brief summary
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
Detailed description
This is a prospective, two-cohort, multicenter clinical study. Subjects received different treatments based on their CPS scores. During induction therapy, subjects in cohort 1 (CPS score ≥10) received adebrelimab, while cohort 2 (CPS score \< 10) were administered adebrelizumab + carboplatin/cisplatin + paclitaxel/nab-paclitaxel. Both groups received carboplatin/cisplatin + paclitaxel/nab-paclitaxel combined radiotherapy during concurrent chemoradiotherapy. The primary endpoint was cCR rate.
Interventions
DRUGadebrelimab
The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
Sponsors
Sun Yat-sen University
Fujian Medical University Union Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-70 years, male or female; 2. Have not received systemic or localized treatment in the past; 3. Histologically or cytologically confirmed esophageal squamous cell carcinoma (AJCC 8th edition clinical stage II-IVA). IVB stage thoracic esophageal cancer with supraclavicular lymph node metastasis only. No surgical resection or refusal of surgical resection; 4. ECOG score of 0-1; 5. Life expectancy ≥ 3 months; 6. Adequate organ function; 7. Fertile men and women must agree to use contraception during the study period and for six months after the last drug used in the study； 8. Subjects will voluntarily enroll in the study, sign an informed consent form, be compliant, and cooperate with follow-up visits.
Exclusion criteria
1. Subjects with low body weight (BMI \<18.5kg/m2) or ≥10% weight loss in the 2 months prior to screening; 2. Esophageal lesions with significant invasion of neighboring organs (e.g., aorta, trachea), or deep and large ulcers with a high risk of bleeding or fistula formation, or previous esophageal perforation or fistula within 6 months prior to screening; 3. Prior treatment with immunotherapy; 4. Treatment with any other clinical investigational drug or participation in another interventional clinical study within 4 weeks prior to first use of study drug; 5. Planning to receive or have received a prophylactic or live attenuated vaccine within 4 weeks prior to the first dose of study drug; 6. Receiving corticosteroid hormone therapy within 2 weeks prior to first use of study drug; 7. Subjects who have received a previous tissue/organ transplant or allogeneic hematopoietic stem cell transplant; 8. Active, known or suspected autoimmune disease; 9. Uncontrolled cardiac clinical symptoms or disease; 10. Active or uncontrolled serious infection (≥ CTCAE grade 2 infection); 11. Subjects with active tuberculosis or a history of active tuberculosis infection within 12 months prior to screening, with or without treatment; 12. History of interstitial lung disease (except radiation pneumonitis not treated with hormonal therapy), or history of non-infectious pneumonia; 13. Active hepatitis B virus or hepatitis C virus infection. Positive HIV test or known acquired immunodeficiency syndrome (AIDS); 14. Prior history of other malignancies within 5 years (except non-melanoma skin cancer, limited prostate cancer, or any early stage tumor treated by radical resection); 15. Known hypersensitivity to any of the investigational drugs or excipients; 16. The presence of other serious physical or mental illnesses or abnormal laboratory tests that may increase the risk of participation in the study or interfere with the results of the study, and subjects who, in the opinion of the investigator, are unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cCR | Up to 6 months. | Clinical complete response rates. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | From date of enrollment until the date of death from any cause, assessed up to 5 years. | Overall survival. |
| PFS | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years. | Progression free survival. |
| ORR | Up to 6 months. | Objective response rate. |
| DCR | Up to 6 months. | Disease control rate. |
| Completion rate of concurrent radiotherapy | Up to 6 months. | Calculate the percentage of patients who have completed concurrent radiochemotherapy. |
| AE | Up to 6 months. | Adverse event, |
| DoR | Up to 3 years. | During of response. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarker analysis | Up to 6 months. | Single-cell sequencing, whole-exome sequencing to screen effective biomarkers and explore their correlation with prognosis. |
Countries
China
Contacts
Primary ContactYong Yang, Doctor
Outcome results
None listed